Iovance Biotherapeutics
Iovance’s cell therapy for skin cancer faces three-year delay due to FDA issues
Anika Sharma
The FDA has introduced a new twist in the ongoing Iovance Biotherapeutics saga, causing further delays in the approval process ...
FDA states that LN-145 in NSCLC is likely to receive accelerated approval
SG Tylor
Source – Iovance Biotherapeutics The Phase II IOV-LUN-202 trial of LN-145 in patients with post-anti-PD-1 non-small cell lung cancer (NSCLC) ...
